186 related articles for article (PubMed ID: 34310723)
41. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center.
Han X; Xu X; Jin D; Wang D; Ji Y; Lou W
Pancreas; 2014 May; 43(4):526-31. PubMed ID: 24658317
[TBL] [Abstract][Full Text] [Related]
43. Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors.
Furukori M; Imai K; Karasaki H; Watanabe K; Oikawa K; Miyokawa N; Taniguchi M; Furukawa H
World J Gastroenterol; 2014 Dec; 20(47):17949-54. PubMed ID: 25548493
[TBL] [Abstract][Full Text] [Related]
44. Pancreastatin predicts survival in neuroendocrine tumors.
Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
[TBL] [Abstract][Full Text] [Related]
45. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).
Hashim YM; Trinkaus KM; Linehan DC; Strasberg SS; Fields RC; Cao D; Hawkins WG
Ann Surg; 2014 Feb; 259(2):197-203. PubMed ID: 24253141
[TBL] [Abstract][Full Text] [Related]
46. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
[TBL] [Abstract][Full Text] [Related]
47. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.
Sallinen VJ; Le Large TYS; Tieftrunk E; Galeev S; Kovalenko Z; Haugvik SP; Antila A; Franklin O; Martinez-Moneo E; Robinson SM; Panzuto F; Regenet N; Muffatti F; Partelli S; Wiese D; Ruszniewski P; Dousset B; Edwin B; Bartsch DK; Sauvanet A; Falconi M; Ceyhan GO; Gaujoux S;
HPB (Oxford); 2018 Mar; 20(3):251-259. PubMed ID: 28988702
[TBL] [Abstract][Full Text] [Related]
48. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.
Faggiano A; Ferolla P; Grimaldi F; Campana D; Manzoni M; Davì MV; Bianchi A; Valcavi R; Papini E; Giuffrida D; Ferone D; Fanciulli G; Arnaldi G; Franchi GM; Francia G; Fasola G; Crinò L; Pontecorvi A; Tomassetti P; Colao A
J Endocrinol Invest; 2012 Oct; 35(9):817-23. PubMed ID: 22080849
[TBL] [Abstract][Full Text] [Related]
49. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors.
Iwata T; Ueno H; Itami J; Ito Y; Inaba K; Morizane C; Kondo S; Sakamoto Y; Shiba S; Sasaki M; Koga F; Okusaka T
Jpn J Clin Oncol; 2017 Sep; 47(9):826-831. PubMed ID: 28591817
[TBL] [Abstract][Full Text] [Related]
51. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
[TBL] [Abstract][Full Text] [Related]
52. Macrovascular venous invasion of pancreatic neuroendocrine tumours: impact on surgical outcomes and survival.
Addeo P; d'Alessandro A; Averous G; Imperiale A; Faitot F; Goichot B; Bachellier P
HPB (Oxford); 2019 Jun; 21(6):653-661. PubMed ID: 30522946
[TBL] [Abstract][Full Text] [Related]
53. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.
Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468
[TBL] [Abstract][Full Text] [Related]
54. It's more than just cancer biology: Health disparities in patients with pancreatic neuroendocrine tumors.
Underwood PW; Riner AN; Neal D; Cameron ME; Yakovenko A; Reddy S; Rose JB; Hughes SJ; Trevino JG
J Surg Oncol; 2021 Dec; 124(8):1390-1401. PubMed ID: 34499741
[TBL] [Abstract][Full Text] [Related]
55. Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study.
Regenet N; Carrere N; Boulanger G; de Calan L; Humeau M; Arnault V; Kraimps JL; Mathonnet M; Pessaux P; Donatini G; Venara A; Christou N; Bachelier P; Hamy A; Mirallié E
Surgery; 2016 Mar; 159(3):901-7. PubMed ID: 26590096
[TBL] [Abstract][Full Text] [Related]
56. A prognostic nomogram in patients with distant metastasis of pancreatic neuroendocrine tumors: a population-based study.
Cai JS; Chen HY; Lu YF; Yu RS
Future Oncol; 2020 Jan; 16(2):4369-4379. PubMed ID: 31802701
[No Abstract] [Full Text] [Related]
57. Prognostic Impact of Tumor Size on Pancreatic Neuroendocrine Tumor Recurrence May Have Racial Variance.
Zheng-Pywell R; Fang A; AlKashash A; Awad S; Reddy S; Vickers S; Heslin M; Dudeja V; Chen H; Rose JB
Pancreas; 2021 Mar; 50(3):347-352. PubMed ID: 33835965
[TBL] [Abstract][Full Text] [Related]
58. Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors.
Gaujoux S; Partelli S; Maire F; D'Onofrio M; Larroque B; Tamburrino D; Sauvanet A; Falconi M; Ruszniewski P
J Clin Endocrinol Metab; 2013 Dec; 98(12):4784-9. PubMed ID: 24057286
[TBL] [Abstract][Full Text] [Related]
59. Multifocality in Small Bowel Neuroendocrine Tumors.
Gangi A; Siegel E; Barmparas G; Lo S; Jamil LH; Hendifar A; Nissen NN; Wolin EM; Amersi F
J Gastrointest Surg; 2018 Feb; 22(2):303-309. PubMed ID: 29119527
[TBL] [Abstract][Full Text] [Related]
60. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR
J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
